Exceptional response to alpelisib in a heavily pretreated patient with metastatic breast cancer carrying a PIK3CA mutation outside SOLAR-1 eligible mutations: a case report

Authors

  • Karolina F. Larsson Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital,Gothenburg, Region Vastra Gotaland, Sweden https://orcid.org/0000-0003-2347-3591
  • Annabelle Forsmark Department of Oncology, Sahlgrenska University Hospital,Gothenburg, Region Vastra Gotaland, Sweden
  • Henrik Fagman Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden; Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Region Vastra Gotaland, Sweden https://orcid.org/0000-0001-5853-6295
  • Maja Drakenberg Danese Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital,Gothenburg, Region Vastra Gotaland, Sweden https://orcid.org/0009-0009-9170-425X
  • Maria Kaire Department of Oncology, Sahlgrenska University Hospital,Gothenburg, Region Vastra Gotaland, Sweden
  • Matilda Liljedahl Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital,Gothenburg, Region Vastra Gotaland, Sweden https://orcid.org/0000-0003-2011-8180
  • Christoffer Vannas Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital,Gothenburg, Region Vastra Gotaland, Sweden; Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden https://orcid.org/0000-0002-1029-0393

DOI:

https://doi.org/10.2340/1651-226X.2026.46486

Keywords:

Breast neoplasms, neoplasm metastasis, precision medicine, molecular-targeted therapy, PIK3CA gene, phosphatidylinositol 3-kinases

Downloads

Download data is not yet available.

References

Liu A, Peng P, Zhu Y, Fei Q, Liu W, Zhang S. Targeted therapies for each subtype of breast cancer. MedComm (2020). 2026;7:e70733. DOI: https://doi.org/10.1002/mco2.70733

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40. DOI: https://doi.org/10.1056/NEJMoa1813904

Drakenberg Danese MB, Vannas CP, Fagman HA, Karlsson PO, Larsson KF. PIK3CA mutation testing and alpelisib use in metastatic breast cancer: a real-world data set. Acta Oncol. 2026;65:401–5. DOI: https://doi.org/10.2340/1651-226X.2026.45589

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–49. DOI: https://doi.org/10.1016/j.annonc.2020.09.010

Kornek G, Selzer E. Targeted therapies in solid tumours: pinpointing the tumour’s Achilles heel. Curr Pharm Des. 2009;15(2):207–42. DOI: https://doi.org/10.2174/138161209787002906

Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473–80. DOI: https://doi.org/10.1038/nrc2394

Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339(22):1609–18. DOI: https://doi.org/10.1056/NEJM199811263392207

Lindman H, Wiklund F, Andersen KK. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden. BMC Cancer. 2022;22(1):1006. DOI: https://doi.org/10.1186/s12885-022-10098-1

Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, et al. Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting. ESMO Open. 2025;10(1):104103. DOI: https://doi.org/10.1016/j.esmoop.2024.104103

Rani A, Stebbing J, Giamas G, Murphy J. Endocrine resistance in hormone receptor positive breast cancer-from mechanism to therapy. Front Endocrinol (Lausanne). 2019;10:245. DOI: https://doi.org/10.3389/fendo.2019.00245

Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol. 2021;12:628690. DOI: https://doi.org/10.3389/fphar.2021.628690

Cardoso F. 7th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC7). Ann Oncol. 2024;35(3):213–32.

Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, et al. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. Lancet Oncol. 2024;25(12):e629–38. DOI: https://doi.org/10.1016/S1470-2045(24)00673-9

Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756. DOI: https://doi.org/10.1016/j.breast.2024.103756

BioInvent International AB. BI-1808 as a single agent and with Pembrolizumab (KEYTRUDA®) in Treatment of Advanced Malignancies (KEYNOTE-D20). Bethesda (MD): U.S. National Library of Medicine; 2021. ClinicalTrialsgov.

Ny L, Fagman H, Botling J, Mantovaara L, Asplund P, Karlsson H, et al. Feasibility and outcome of genomics-guided treatment selection in advanced cancer – the MEGALiT explorative clinical trial. Acta Oncol. 2025;64:742–50. DOI: https://doi.org/10.2340/1651-226X.2025.43366

Food US, Drug A. FoundationOne CDx (F1CDx) – P170019/S048. Silver Spring (MD): U.S. Food and Drug Administration; 2023. FDA Recently Approved Devices.

Rugo HS, Raskina K, Schrock AB, Madison RW, Graf RP, Sokol ES, et al. Biology and targetability of the extended spectrum of PIK3CA mutations detected in breast carcinoma. Clin Cancer Res. 2023;29(6):1056–67. DOI: https://doi.org/10.1158/1078-0432.CCR-22-2115

Martínez-Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22(1):45. DOI: https://doi.org/10.1186/s13058-020-01284-9

Tharin Z, Richard C, Derangère V, Ilie A, Arnould L, Ghiringhelli F, et al. PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy. Sci Rep. 2023;13(1):4467. DOI: https://doi.org/10.1038/s41598-023-31593-w

Schagerholm C, Robertson S, Toosi H, Sifakis EG, Hartman J. PIK3CA mutations in endocrine-resistant breast cancer. Sci Rep. 2024;14(1):12542. DOI: https://doi.org/10.1038/s41598-024-62664-1

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427–38.e6. DOI: https://doi.org/10.1016/j.ccell.2018.08.008

Jenkins ML, Ranga-Prasad H, Parson MAH, Harris NJ, Rathinaswamy MK, Burke JE. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus. Nat Commun. 2023;14(1):181. DOI: https://doi.org/10.1038/s41467-023-35789-6

Geering B, Cutillas PR, Nock G, Gharbi SI, Vanhaesebroeck B. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc Natl Acad Sci U S A. 2007;104(19):7809–14. DOI: https://doi.org/10.1073/pnas.0700373104

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. DOI: https://doi.org/10.1126/science.1096502

Burke JE, Perisic O, Masson GR, Vadas O, Williams RL. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci U S A. 2012;109(38):15259–64. DOI: https://doi.org/10.1073/pnas.1205508109

Institute NC. [cited 2025 Oct 14]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/targeted-therapy2025

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058–70. DOI: https://doi.org/10.1056/NEJMoa2214131

Nilbert M. The promises of precision medicine – voices from the Nordics. Acta Oncol. 2025;64:775–7. DOI: https://doi.org/10.2340/1651-226X.2025.43987

Downloads

Published

2026-09-23

How to Cite

Larsson, K. F., Forsmark, A., Fagman, H., Drakenberg Danese, M., Kaire, M., Liljedahl, M., & Vannas, C. (2026). Exceptional response to alpelisib in a heavily pretreated patient with metastatic breast cancer carrying a PIK3CA mutation outside SOLAR-1 eligible mutations: a case report. Acta Oncologica, 65, 776–780. https://doi.org/10.2340/1651-226X.2026.46486

Issue

Vol. 65 (2026): Acta Oncologica

Section

Letter

Categories

License

Copyright (c) 2026 Karolina F. Larsson, Annabelle Forsmark, Henrik Fagman, Maja Drakenberg Danese, Maria Kaire, Matilda Liljedahl, Christoffer Vannas

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.